MedTrace Logo

Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine

NCT03161366 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2018-12-19

No results posted yet for this study

Summary

Interventional, single arm, open-label, non-randomized, phase IIIb study to accumulate additional data on safety and effectiveness of one dose of rVSVΔG-ZEBOV-GP against Ebola virus disease.

Conditions

  • Ebola Virus Disease

Interventions

BIOLOGICAL

rVSVΔG-ZEBOV-GP

Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case

Sponsors & Collaborators

  • Medecins Sans Frontieres, Netherlands

    collaborator OTHER

  • Epicentre

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-28
Primary Completion
2018-07-14
Completion
2018-11-30

Countries

  • Democratic Republic of the Congo
  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03161366 on ClinicalTrials.gov